Home
Publications
Posters
NK cell recruitment into A549 TME in genO-BRGSF-HIS mice

NK cell recruitment into A549 TME in genO-BRGSF-HIS mice

TME composition in genO-BRGSF-HIS mice

November 8, 2025

Background

‍

Related products

Catalogue product

genO‑BRGSF‑HIS

genO‑BRGSF‑HIS mice possess the most functional reconstituted human immune system currently on the market and are highly relevant for translational research.

Customized product

No items found.
Related posters
Tumor cell line-derived xenograft subtype shapes tumor microenvironment composition in genO-BRGSF-HIS mice

TME composition in genO-BRGSF-HIS mice

Apr 2025
Functional γδ T cells in genO-BRGSF-HIS mice

γδ T cells in genO-BRGSF-HIS

Apr 2025
Tumor microenvironment composition is shaped by tumor cell line-derived xenograft subtype and tumor burden in BRGSF-HIS mice

TME composition in BRGSF-HIS mice

Nov 2024
Assessment of γδ T-cell therapies in humanized mice

BRGSF-HIS for γδ T-cell therapies

Nov 2024
BRGSF-HIS mice as a predictive tool for safety assessment of biologics

BRGSF-HIS for safety assessment

Sep 2024
(Sensei) SNS-101, a monoclonal antibody that is highly selective for VISTA in the tumor microenvironment, demonstrates favorable pharmacokinetic and cytokine release characteristics and potentiates anti-PD-1 responsiveness

VISTA in the tumor microenvironment

Apr 2022
(Macomics) Discovery of MACO355: a first in mechanism ligand-blocking independent LILRB1/2/3 antibody for cancer therapy

In vivo tumor growth suppression

Apr 2024
Tumor cell line-derived xenograft subtype shapes tumor microenvironment composition in BRGSF-HIS mice

BRGSF-HIS & tumor microenvironment

Apr 2024
Functional human myeloid cells in BRGSF-HIS humanized mice enable myeloid-directed therapy assessment

BRGSF-HIS for myeloid-directed therapy assessment

Apr 2023
Myeloid cells' contribution is key in CRS pathophysiology induced by T-cell engagers in BRGSF-HIS model

BRGSF-HIS & myeloid cell compartment in CRS

Nov 2023
Cell-depleting agents assessment in preclinical models

BRGSF-HIS & hFcγR to assess cell depletion

Nov 2023
Translatable preclinical mouse models for assessment of T-cell engager-induced CRS

BRGSF-HIS & CD3ε in CRS

Apr 2022
CD3 humanized mouse models as validated tools to assess immune-related adverse events of T-cell engagers

CD3 and BRGSF-HIS to assess IrAEs

Nov 2022
Anti-VISTA agents profiling: complementarity of BRGSF-HIS and hVISTA Knock-in as preclinical models for immunotherapies

BRGSF-HIS & hVISTA for immunotherapies

Nov 2022
Show all posters
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe

BRGSF